These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23809741)

  • 21. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan.
    Igari H; Watanabe A; Chiba H; Shoji K; Segawa S; Nakamura Y; Watanabe M; Suzuki K; Sato T
    Jpn J Infect Dis; 2011; 64(3):177-82. PubMed ID: 21617299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.
    Bettinger JA; Rouleau I; Gariepy MC; Bowie WR; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; McNeil SA; McCarthy A; De Serres G;
    Euro Surveill; 2015 Jul; 20(29):21189. PubMed ID: 26227369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.
    Kurz X; Domergue F; Slattery J; Segec A; Szmigiel A; Hidalgo-Simon A
    Vaccine; 2011 Jun; 29(26):4378-87. PubMed ID: 21501644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy).
    Amodio E; Anastasi G; Marsala MG; Torregrossa MV; Romano N; Firenze A
    Vaccine; 2011 Feb; 29(7):1408-12. PubMed ID: 21199700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers.
    Mascagni P; Vicenzi E; Kajaste-Rudnitski A; Pellicciotta G; Monti A; Cervi C; Vitalucci R; Toffoletto F
    Med Lav; 2012; 103(3):220-9. PubMed ID: 22838300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination against pandemic influenza A/H1N1 among healthcare workers and reasons for refusing vaccination in Istanbul in last pandemic alert phase.
    Torun SD; Torun F
    Vaccine; 2010 Aug; 28(35):5703-10. PubMed ID: 20600497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal influenza vaccination predicts pandemic H1N1 vaccination uptake among healthcare workers in three countries.
    Chor JS; Pada SK; Stephenson I; Goggins WB; Tambyah PA; Clarke TW; Medina M; Lee N; Leung TF; Ngai KL; Law SK; Rainer TH; Griffiths S; Chan PK
    Vaccine; 2011 Oct; 29(43):7364-9. PubMed ID: 21807048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring adverse events of vaccines against Mexican flu.
    van Puijenbroek EP; van Grootheest AC
    Int J Risk Saf Med; 2011; 23(2):81-7. PubMed ID: 21673415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination].
    Ji WY; Lu L; Lü M; Miao L; Gao T; Huang RG; Suo LD; Liu DL; Ma R; Yu R; Zhangzhu JZ; Liu WX; Zeng Y; Li XM; Wu J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 May; 31(5):481-4. PubMed ID: 21163019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands.
    van Puijenbroek EP; Broos N; van Grootheest K
    Drug Saf; 2010 Dec; 33(12):1097-108. PubMed ID: 21077700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].
    Alguacil Ramos AM; Lluch Rodrigo JA; Portero Alonso A; Martín Ivorra R; Pastor Villalba E
    Rev Esp Salud Publica; 2012; 86(3):241-51. PubMed ID: 22991081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces--2009-2010.
    Mayet A; Ligier C; Gache K; Manet G; Nivoix P; Dia A; Haus-Cheymol R; Verret C; Duron S; Faure N; Piarroux M; De Laval F; Simon F; Decam C; Chaudet H; Meynard JB; Rapp C; Deparis X; Migliani R
    Vaccine; 2011 Mar; 29(14):2576-81. PubMed ID: 21296693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.
    Saariaho AH; Vuorela A; Freitag TL; Pizza F; Plazzi G; Partinen M; Vaarala O; Meri S
    J Autoimmun; 2015 Sep; 63():68-75. PubMed ID: 26227560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pandemic influenza A (H1N1)v vaccination status and factors affecting vaccination: Ankara and Diyarbakır 2009 data from Turkey].
    Ertek M; Sevencan F; Kalaycıoğlu H; Gözalan A; Simşek C; Culha G; Dorman V; Ozlü A; Arıkan F; Aktaş D; Akın L; Korukluoğlu G; Sevindi DF
    Mikrobiyol Bul; 2011 Oct; 45(4):684-96. PubMed ID: 22090299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Review of the sudden death and death following immunization of influenza vaccine].
    Li KL; Wu WD; Liu DW
    Zhongguo Yi Miao He Mian Yi; 2010 Jun; 16(3):270-4. PubMed ID: 20726274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.